Sarepta Therapeutics Inc (SRPT)
Pretax margin
| Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | ||
|---|---|---|---|---|---|---|
| Earnings before tax but after interest (EBT) | US$ in thousands | 260,774 | -520,098 | -689,963 | -418,948 | -553,065 |
| Revenue | US$ in thousands | 1,901,980 | 1,243,340 | 933,013 | 701,887 | 540,099 |
| Pretax margin | 13.71% | -41.83% | -73.95% | -59.69% | -102.40% |
December 31, 2024 calculation
Pretax margin = EBT ÷ Revenue
= $260,774K ÷ $1,901,980K
= 13.71%
The pretax margin of Sarepta Therapeutics Inc has shown significant fluctuations over the past five years based on the provided data. The margin was deeply negative in December 2020 at -102.40%, indicating that the company's expenses outweighed its revenue before accounting for taxes.
However, there was a notable improvement by December 2024, with the pretax margin turning positive at 13.71%. This indicates that the company was able to generate more revenue compared to its expenses before tax deductions during that period.
It is important to note that the pretax margin is a key profitability metric and reflects the company's ability to control costs and operate efficiently. The fluctuations in Sarepta Therapeutics Inc's pretax margin over the years suggest varying levels of operational performance and financial health. Further analysis and comparison with industry peers would provide a more comprehensive understanding of the company's financial standing.
Peer comparison
Dec 31, 2024